MedTrace Logo

Antidiabetic Medications and Risk of Cancer

NCT07628556 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74799

Last updated 2026-06-05

No results posted yet for this study

Summary

A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.

Conditions

Interventions

DRUG

Metformin

Metformin monotherapy

DRUG

sulphonylurea

SU monotherapy

DRUG

DPP-4 inhibitor

DPP-4 inhibitor monotherapy

DRUG

GLP-1 Receptor Agonists

GLP-1 Receptor Agonist monotherapy

DRUG

SGLT-2 inhibitor

SGLT-2 inhibitor monotherapy

DRUG

insulin

Insulin monotherapy

DRUG

MET + SU

MET + SU combination

DRUG

MET + DPP-4 inhibitor

MET + DPP-4 inhibitor combination

DRUG

MET + GLP-1RA

MET + GLP-1RA combination

DRUG

MET + SGLT2i

MET + SGLT2i combination

DRUG

MET + INS

MET + insulin combination

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Principal Investigators

  • György Rokszin, M.D., Ph.D.

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-15
Primary Completion
2025-12-30
Completion
2025-12-30
FDA Drug
Yes

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07628556 on ClinicalTrials.gov